In an effort to broaden its impact and improve the quality of life for patients with Inflammatory Bowel Disease (IBD), Arena Pharmaceuticals has introduced the Arena of Care Award in IBD, a competitive grant program to support the development and implementation of innovative community-based services and initiatives that address unmet need(s) of those impacted by IBD.
Successful proposals for the Arena of Care Award will meet one or more of the following key objectives: increase capacity for innovative programs that address unmet need(s) of the IBD community; increase understanding of IBD through education that shifts perspectives and perceptions to reduce misconceptions and stigma associated with the disease; increase opportunities for IBD stakeholder (e.g., patients, parents/guardians, caregivers) engagement in the development and delivery of IBD education, awareness, and support services; increase health care and service provider awareness of IBD through targeted education and/or training (e.g., IBD information dissemination at primary and specialty HCP offices, outpatient clinics, hospitals, and other community points of care); and reduce disparities in access to IBD health care and support services among patients of diverse ethnic and racial backgrounds, and among other traditionally underserved patient.
The annual maximum award amount for an individual organization is $25,000 and $50,000 for collaborative proposals involving two or more organizations). For collaborative proposals, one organization must identify as the applicant, and the other(s) as collaborative partner(s). The applicant must include in the proposal a single budget of up to $50,000 that details how the partner(s) will be compensated/involved with the project. The applicant must also submit a Memorandum of Understanding with the proposal.
Applications are due August 31. (Early submissions are encouraged to avoid technical issues.) Awards will be announced between November 1 and December 1, with projects expected to start January 1, 2021, and end by December 31, 2021.
For the complete RFP, including award details, application instructions, and a proposal scoring rubric, see the Arena Pharmaceutical website.